Overview

Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer

Status:
Not yet recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this clinical trial is to evaluate the efficacy and safety of Utidelone plus AC versus Docetaxel plus AC as neoadjuvant chemotherapy in high-risk HER2-negative early-stage or locally advanced breast cancer. In this phase III, multi-center, open-label, randomized controlled study, 552 subjects will be enrolled and randomly assigned in a 1:1 ratio to either the Utidelone plus AC group or the docetaxel plus AC group, stratified by hormone receptor status (ER and/or PgR positive vs ER and PgR negative).

Phase:

Phase 3

Details

Lead Sponsor:

Beijing Biostar Pharmaceuticals Co., Ltd.

Treatments:

Docetaxel